Allgenesis Biotherapeutics Inc.
Allgenesis is a privately owned, clinical stage, biopharmaceutical company based in Taipei City, Taiwan. Its mission is to find solutions for major eye diseases affecting millions worldwide and to establish a world-renowned biopharmaceutical business in Taiwan by inventing and developing novel medicines for the global market.
Industries
Nr. of Employees
small (1-50)
Allgenesis Biotherapeutics Inc.
Patents
Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US-11369600-B2
View Details
Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US-11369600-B2
View DetailsProducts
AG-73305
Bispecific biologic combining anti-VEGF activity and integrin/disintegrin-based activity formulated as an intravitreal therapeutic for retinal diseases.
AG-80308
A formyl peptide receptor (FPR) agonist developed for treatment of dry eye and ocular inflammation; noted as an in-licensed clinical candidate.
AG-86893
A tyrosine kinase inhibitor developed as a topical ophthalmic candidate for pterygium; referenced as a 505(b)(2) pathway program.
Disintegrin platform
A biologic platform using disintegrin-based mechanisms intended to modulate integrin pathways for retinal disease indications.
AG-73305
Bispecific biologic combining anti-VEGF activity and integrin/disintegrin-based activity formulated as an intravitreal therapeutic for retinal diseases.
AG-80308
A formyl peptide receptor (FPR) agonist developed for treatment of dry eye and ocular inflammation; noted as an in-licensed clinical candidate.
AG-86893
A tyrosine kinase inhibitor developed as a topical ophthalmic candidate for pterygium; referenced as a 505(b)(2) pathway program.
Disintegrin platform
A biologic platform using disintegrin-based mechanisms intended to modulate integrin pathways for retinal disease indications.
Services
Design and conduct of early‑phase ophthalmology clinical studies including protocol development, site management and patient recruitment.
Design and oversight of nonclinical pharmacology, PK, toxicology and ocular pathology studies to support IND-enabling packages.
Analytical method development, formulation and process development support for biologic drug substance and drug product.
Regulatory planning and preparation for health‑authority meetings and submissions (Pre‑IND/IND and related interactions).
Assessment and integration of in‑licensed candidates into the company pipeline and engagement in business development activities.
Design and conduct of early‑phase ophthalmology clinical studies including protocol development, site management and patient recruitment.
Design and oversight of nonclinical pharmacology, PK, toxicology and ocular pathology studies to support IND-enabling packages.
Analytical method development, formulation and process development support for biologic drug substance and drug product.
Regulatory planning and preparation for health‑authority meetings and submissions (Pre‑IND/IND and related interactions).
Assessment and integration of in‑licensed candidates into the company pipeline and engagement in business development activities.
Expertise Areas
- Clinical trial management (ophthalmology)
- Ophthalmic drug discovery and preclinical development
- Biologic therapeutics development
- Small-molecule ophthalmic development
Key Technologies
- Bispecific biologics (Fc-fusion)
- Disintegrin-based biologic platforms
- Small-molecule tyrosine kinase inhibitors
- Formyl peptide receptor (FPR) agonists